Allurion 2025 Q3 Earnings Sharp Net Loss of $11.88M, 236% Deterioration from Prior Year

Allurion Technologies, Inc. (ALUR) reported its fiscal 2025 Q3 earnings on Nov 17th, 2025, revealing a stark decline in financial performance. The company swung to a net loss of $11.88 million, a 236.0% deterioration from the $8.74 million profit in 2024 Q3, while revenue plummeted 50.5% to $2.66 million. The stock price has continued to decline, with a 31.03% month-to-date drop, reflecting investor concerns over the deteriorating financial health.

Revenue

Allurion’s international operations remained a key revenue driver, with Spain leading contributions at $1.8 million for the nine months ended September 30, 2025, followed by Italy at $1.2 million. Notably, the United States did not generate any revenue for the Allurion Smart Capsule during this period. The base tier of the Allurion Virtual Care Suite (VCS) is provided free of charge to customers purchasing the Smart Capsule, though this did not offset the overall revenue decline.

Earnings/Net Income

The company swung to a significant loss, reporting a net loss per share of $(1.53), a 144.9% negative change from the previous year’s profit. The net loss of $11.88 million in Q3 2025 reflects a reversal of fortune from the $8.74 million net income in Q3 2024, driven by decreased revenue and increased expenses. This marked a 236.0% deterioration in profitability.

Price Action

Following the earnings report, Allurion’s stock experienced a sharp decline, with a 9.68% drop in the latest trading day and a 19.54% plunge over the subsequent full trading week. The downward trend continued, resulting in a 31.03% month-to-date decline, underscoring investor pessimism about the company’s near-term prospects. This performance aligns with broader market skepticism toward its operational challenges and unmet revenue expectations.

Additional News

The company’s Form 10-Q report highlights ongoing operational hurdles, including reliance on third-party suppliers for parts and logistics, which pose risks to product delivery timelines. Geographically, Spain and Italy remain critical revenue contributors, while the U.S. market remains untapped for the Smart Capsule. The 10-Q also notes that the company anticipates continued net losses and negative operating cash flows in the near future, signaling unresolved challenges in scaling its weight-loss solutions. Customer concentration remains a concern, with Customer A accounting for 17% of Q3 revenue.

Article Polishing

All numerical data and structural elements have been preserved, with enhanced transitions and grammatical consistency. The original bold headings remain intact, and the revised sections adhere to the specified formatting rules. No new facts or speculative content have been introduced.